QualityStocks
  The QualityStocks Daily Newsletter for Monday, June 7th, 2010 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters

1.

Penny Stock Chaser (MOPN)

2.

Stock Source (FDFM)

3.

Penny Trader (SSWC)


The QualityStocks Daily

Li3 Energy, Inc. (LIEG)

Daily Profit, Weiss Research, Stock Research Newsletter, Another Winning Trade, The Trading Report, and The Stock Advisors reported  recently on Li3 Energy, Inc. (LIEG),  HotOTC.com, Cool Penny Stocks, Stock Rich, and Small Cap Voice reported earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Lima, Peru, Li3 Energy, Inc. is an early stage company currently pursuing a business strategy in the lithium brine mining and energy sector in the Americas. Lithium brines are recognized as a faster, lower-cost, more energy efficient, and environmentally friendly source of extraction than hard rock lithium mining. The Company's initial focus is on identifying and acquiring opportunities in Peru, Argentina, Chile, and the United States. Li3 Energy, Inc. trades on the OTC Bulletin Board.

Li3 Energy is working to acquire a significant portfolio of lithium brine deposits in the Americas for the purpose of development and production. This is to meet growing market demand and to support the clean energy and green energy initiatives undergoing implementation globally. The Company has a management team and board of directors with extensive resource sector, corporate development, and finance expertise. Li3 Energy's technical team has direct experience successfully exploring and producing lithium resources.

The Company signed a letter of intent to purchase options to acquire up to an aggregate 80 percent interest in eleven lithium brine properties covering 123,000 acres in Chile and options to acquire an 85 percent interest in four lithium brine properties covering 90,000 acres in Argentina. The prospects are within the Puna Plateau, which hosts 70 percent of the world's lithium reserves.

Li3 Energy announced in March 2010 that they closed their agreement to acquire the assets of Next Lithium Corp. They acquired a 100 percent interest in 170,000 acres of a strategically located property prospective for lithium brine, located in Big Smoky Valley near Tonopah, Nevada.

Li3 Energy, Inc. also announced in March that they executed definitive purchase agreements to acquire the rights of Puna Lithium Corporation over certain Argentinean assets. The rights include three options to acquire from Lacus Minerals S.A. up to an aggregate of 85 percent interest in approximately 90,000 acres situated on prospective brine salars (salt flats) in Argentina. The rights also include the acquisition of Noto Energy S.A., an Argentinean corporation, which owns a 100 percent interest over 2,995 acres also situated on promising brine salars in Argentina.

The Company launched the 2010 exploration program on their Puna Lithium Properties in April. The design of the program is to test the lithium-brine production potential of Li3 Energy's salar (dry salt lake) properties on the Puna Plateau of northern Argentina.

Li3 Energy, Inc. (LIEG) closed Monday's trading at $0.39 up 2.63 percent. Volume was 110,470.

AISystems, Inc. (ASYI)

Today, Wall Street Grand and Beacon Equity Research reported on AISystems, Inc. (ASYI), Micro Stock Profit, Chart Advisor, Penny Stock Finder, Whisper from Wall Street did last week. The Stock Psycho, PennyProphet.com, SmallCap Voice, did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, AISystems, Inc. is a company that has developed a proprietary business platform software-system for the airline industry called jetEngine™. It consists of systems and mathematical algorithms capable of generating significant profitability improvements through strategic business planning capabilities, resource scheduling, revenue management, and integrated operations. AISystems, Inc. has their headquarters in Kirkland, Washington. They also have an office in Toronto, Ontario.

jetEngine™ is a new platform for strategic airline management. It enhances business planning and operational capabilities through the holistic integration of these activities in real time. The total potential market for the jetEngine™ platform includes all commercial airlines.

The Company's platform generates a fully feasible route, fleet, crew and maintenance solution. It reduces the business planning process from weeks to minutes, and the basing of schedules is on clean-slate designs. It also provides financial projections that are more accurate, due to minimizing the number of assumptions required.

It enables airlines to model the impact of external factors and competitor actions, and simplifies the planning process by greatly reducing manual processes and interaction of planning departments.
in addition, it reduces costs significantly, and enables carriers to focus constantly on profitability.

Today, AISystems, Inc. announced that they would release their crew scheduling and rostering technology in 2011. This technology allows airlines to create crew schedules and rosters in minutes. It also allows scheduling changes, which are guaranteed not to adversely affect the efficiency of the schedule plan. The technology is proprietary to AISystems, Inc.

Stephen Johnston, President/CEO of AISystems commented, "The Company is very pleased with the initial results of our Crew Scheduling and Rostering prototype. Our technology should provide airlines with immediate and direct improvement to profitability, as well as facilitating greater efficiency in their logistics operations. It also creates a more user-friendly and efficient experience for crew members when they bid on desired routes and schedules. The new Crew Scheduling and Rostering Technology is expected to be made available to the market in 2011."

AISystems, Inc. (ASYI) closed Monday's trading session at $0.54 up 8.00 percent. Volume was 389,163.

Bark Group Inc. (BKPG)

Today, Stock Guru, Stock Bully, Penny Stock Finder, Stock Source, and Stockwire reported on Bark Group Inc. (BKPG), Greenbackers and Invest Source did last week, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Bark Group Inc. is a company that delivers advertising and marketing campaigns to leading European businesses. The Company develops and delivers highly effective marketing campaigns on structural, strategic, and emotional and creative levels. Bark's objectives are to achieve aggressive growth through acquisition and development of satellite companies around the globe, starting with Europe. They have their U.S. base in New York, New York, and Copenhagen headquarters in Denmark. Bark has many of their international clients in Scandinavia and Europe. The Company trades on the OTC Bulletin Board.

Bark Group's campaigns integrate classic and digital media as well as viral and other forms of communication. Their integrated approach is innovating in the communications field, while offering clients a higher return on their advertising investments.

Bark collaborates with Mindmetic, a mind research company developing neuro-marketing research methods. Mindmetic studies and develops methods for interpreting and decoding conscious and subconscious human emotions that arise when people are subjected to different messages. Bark Group Inc. will soon take advantage of this research and use it in their marketing campaigns.

Bark Group Inc. announced recently their financial results for the first quarter ended March 31, 2010. Highlights of the First Quarter include acquisition of 51 percent interest in Anaconda TV GmbH. They are a leading international television format and production company incorporated in Munich, Germany.

Bark Group's revenues increased to $1,364,000 during the three months ended March 31, 2010, compared to $1,243,000 during the three months ended March 31, 2009. This represents an increase of $121,000 or 10 percent. Net loss declined to $302,000 for the three months ended March 31, 2010, compared to a net loss of $530,000 for the three months ended March 31, 2009. This represents a decrease of $228,000.

Today, Bark Group Inc. announced that their affiliate, Bark Copenhagen, won the account of NUPO, a prestigious diet product brand. NUPO has been produced and sold since 2000 by Flex Pack A/S, a Danish consumer goods company. Bark Copenhagen, NUPO'S new marketing agency, will manage all strategic developmental processes of new products and markets. They will also oversee the creative and tactical implementation of communications, through different media outlets.

Bark Group Inc. (BKPG) closed Monday's session at $0.11 up 22.22 percent. Volume was 1,577,716.

Manas Petroleum Corp. (MNAP)

Today, Undiscoveredequities.com reported on Manas Petroleum Corp. (MNAP), OTC Picks did recently, and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, Manas Petroleum Corp. is an international oil exploration and development company. They have their corporate headquarters in Baar, Switzerland. Founded in 2004, the Company spent their first two years acquiring and developing their Kyrgyz Republic, Tajikistan, and Albanian projects. Their portfolio now totals more than 5 million acres in 5 countries.  

The Company's focus is on exploring and developing projects in Southeastern Europe, Central Asia, and South America. Specific countries are Albania, Mongolia, Kyrgyzstan, Tajikistan, and Chile. Manas are currently maturing their significant resource potential by acquiring seismic and drilling.

The Company acquired three production-sharing agreements (PSCs) covering six blocks on the northern flank of Albania's oil rich fold and thrust belt. The agreements, which cover blocks A, B, D, E, 2 and 3 received approval by the National Agency of Natural Resources (AKBN) and was ratified by the Energy Ministry. In February 2010, Manas completed the transaction concerning their Albanian project with Petromanas Energy Inc., in exchange for cash and shares of Petromanas Energy Inc.

In Kyrgyzstan, Manas acquired six exploration licenses covering 3,152 square kilometers in the Kyrgyz Republic. The licenses lie within a proven petroleum system known as the Fergana Basin. The Basin extends across parts of Kyrgyz Republic and into Uzbekistan and Tajikistan. Manas' technical team has already identified many deep structures on their licenses.

Manas, together with partner IPR (Independent Petroleum Resources, a Texas based independent) won the bid for the Tranquillo block in Chile.  The Tranquillo block is in a thrust belt environment and has a considerable number of target structures of both shallow and moderate depth, with potential for significant GIIP figures. The Tranquillo block has a proven petroleum system, and though the main potential is gas, based on discoveries on the Argentina side of the basin, there is a chance of liquids production.
   
In early December 2009, Manas Petroleum reported that DWM Petroleum completed their year-1 work program on blocks 13 and 14 in Mongolia, ahead of schedule. The original expectation was that the work would undergo completion on April 21, 2010. Boris Goldinshtein, Manas' General Manager for Central Asia, managed the operation with operations being performed by Manas Gobi ltd., located in Ulan Bataar.

Manas Petroleum Corp.'s wholly owned subsidiary DWM Petroleum AG commenced the first part of a 600 km 2-D seismic program in Albania in 2008. The seismic crew continued the program in 2009.

Today, Manas Petroleum Corp. reported that their 90 percent owned subsidiary CJSC Somon Oil completed the acquisition of a 363 km 2D seismic program in Tajikistan, on budget and on schedule. This seismic is to further define and analyze the extension of the Tuzluk structural trend (prospects delineated in the Kyrgyz Tuzluk license). It is also to mature a number of Tajik prospects to drill-ready status on this trend. The trend is in the Manas Western license area in Tajikistan.

Manas Petroleum Corp. (MNAP) closed Monday's session at $0.65 up 1.56 percent. Volume was 52,546.

La Cortez Energy, Inc. (LCTZ)

We are highlighting La Cortez Energy, Inc. (LCTZ), here at the QualityStocks Daily Newsletter.

Trading on the OTC Bulletin Board, La Cortez Energy, Inc. is an early stage oil and gas exploration and production company. The Company is currently pursuing a business strategy in the energy sector in South America. La Cortez Energy, Inc. has their headquarters in Bogota, Colombia, South America.

The Company is concentrating their efforts initially in Colombia, where, they believe good exploration and production opportunities exist with straightforward oil and gas contracting terms and conditions. Later, they plan to turn to opportunities in other regional countries. Within the arena of the oil and gas business, the Company plans to focus on a blend between exploration and production of hydrocarbons via a variety of transactions.

Company management is mainly interested in developmental properties where some combination of different factors exists. These factors include opportunities for medium-to-long-term production life with clear understandings of production mechanisms and output levels. These factors also include geological formations with multiple producing horizons, substantial upside potential, as well as relatively low capital investment and production costs.

La Cortez Energy, Inc. established a branch, La Cortez Energy Colombia, Inc., with offices in Bogota, Colombia. They also signed a Joint Operating Agreement for a 50 percent working interest in the Putumayo-4 block and a farm-in agreement for a 20 percent working interest in the Maranta block, both in Colombia.

On March 4, 2010, La Cortez Energy, Inc. and Avante Petroleum S.A. announced the signing of a stock purchase agreement for and simultaneous closing of La Cortez' acquisition of Avante's subsidiary Avante Colombia S.a.r.l. in exchange for common stock of La Cortez.  The purchase includes Avante Colombia's Colombian branch, Avante Colombia Ltd. Sucursal. Avante holds interests in oil fields covering 11,535 acres in the Catatumbo region in northeast Colombia.

Avante Colombia currently has a 50 percent participation interest and is the operator of the Rio de Oro and Puerto Barco production contracts with Ecopetrol in the Catatumbo area, under an operating joint venture with Vetra Exploracion y Produccion S.A.  La Cortez and Avante also agreed to enter into a joint venture to develop further exploration opportunities in Colombia.

On May 27, 2010, La Cortez Energy, Inc. announced that Emerald Energy Plc. has begun drilling operations for the Mirto-2 exploratory well. Emerald is the operator of the Maranta Block where La Cortez will hold a 20 percent working interest. The Maranta block covers an area of 90,459 acres (36,608 hectares) in the foreland of the Putumayo Basin in southwest Colombia.

La Cortez Energy, Inc. (LCTZ) closed Monday's trading session at $2.18 up 2.83 percent. Volume was 24,910.

Javelin Pharmaceuticals Inc. (JAV)

Today, Penny Omega and SmallCap Voice reported on Javelin Pharmaceuticals Inc. (JAV), Greenbackers and Stock Traders Chat did last week, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Javelin Pharmaceuticals Inc., with their subsidiaries, engages in the research, development, and commercialization of pharmaceutical products for pain relief in the United States and Europe. Founded in 1998, the Company trades on the NYSE Amex. They have their corporate headquarters in Cambridge, Massachusetts.

As a specialty pharmaceutical company, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs. Their product candidates address the acute moderate-to-severe pain medication market. Indications they are developing include post-operative pain, orthopedic injury pain, procedural pain, burn pain, and trauma.

Javelin Pharmaceuticals Inc. has one marketed product - Dyloject® - in the United Kingdom. In the United States, they have submitted a New Drug Application (NDA) for Dyloject™ and have two drug candidates in US Phase III clinical development. These are Ereska™ (intranasal ketamine) and Rylomine™ (intranasal morphine). Javelin is currently seeking licensing partners for their late stage development product candidates.

Javelin Pharmaceuticals has a license agreement with Shimoda Biotech, Ltd.  This is to develop and commercialize products related to a proprietary formulation of the injectable delivery of diclofenac. They also have a license agreement with West Pharmaceutical Services, Inc. This is to develop and commercialize intranasal morphine for the transmucosal delivery of morphine to humans and animals for the treatment of pain.

Today, Javelin Pharmaceuticals, Inc. announced that on June 4, 2010, Javelin received notice from Hospira, Inc. that Hospira will fund a $2 million loan to Javelin on June 10, 2010 under the existing loan agreement between Javelin and Hospira.

Also on June 4, Javelin was informed that the Delaware Court of Chancery granted Javelin's motion to expedite proceedings, and a trial date of July 26, 2010 has been set for the lawsuit filed by Javelin. This is against Hospira and their wholly owned subsidiary, Discus Acquisition Corporation (Discus), seeking to compel Hospira and Discus to complete the agreed-upon merger pursuant to the definitive merger agreement among Javelin, Hospira and Discus dated April 17, 2010.

Javelin Pharmaceuticals Inc. (JAV) closed today at $1.43 up 8.33 percent. Volume was 2,671,424.

Blue Dolphin Energy Company (BDCO)

Penny Invest, StockEgg.com, and All Penny Stocks reported earlier on Blue Dolphin Energy Company (BDCO), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.

Blue Dolphin Energy Company engages in the gathering and transportation of natural gas and condensate and production of oil and gas in the Gulf of Mexico. The Company's activities fall within two primary business segments. One is pipeline transportation and related services for producers/shippers. The other is oil and gas exploration and production. Blue Dolphin Energy Company trades on the NASDAQ Capital Market. Their headquarters are in Houston, Texas.

The Company carries out most of their operations via their wholly owned subsidiaries. These are Blue Dolphin Pipe Line Company, Blue Dolphin Petroleum Company, Blue Dolphin Exploration Company, and Blue Dolphin Services Co.

The Blue Dolphin Pipeline System is the Company's primary pipeline asset. The Blue Dolphin Pipeline is a 20-inch crude oil and natural gas pipeline. It is approximately 40 miles long and runs from their offshore platform in the Galveston area in the Gulf of Mexico to their onshore facilities near Freeport, Texas.  The pipeline also connects the onshore facilities to an intrastate pipeline system and major chemical plants complex.

The system includes the Blue Dolphin Pipeline, an offshore platform for separation, metering and compression, the onshore Buccaneer oil pipeline, onshore facilities including 85,000 barrels of above ground tankage, separation and dehydration facilities, a barge loading terminal and 360 acres of land.

Blue Dolphin's Galveston Area Block 350 Pipeline is an 8-inch pipeline approximately 13 miles long in the Galveston area of the Gulf of Mexico. It has a subsea interconnection to a major interstate pipeline system.

The Company's Omega Pipeline is a 12-inch pipeline approximately 18 miles long. It extends from the West Cameron area off the Louisiana coast to the High Island area off the Texas coast in the Gulf of Mexico.  The pipeline is currently inactive.

Blue Dolphin Energy Company's oil and gas exploration and production activities focus on the Western Gulf of Mexico off the coasts of Texas and Louisiana. Their activities there include the exploration, acquisition, development, and operation of oil and gas properties. They currently own interests in three blocks in the High Island area in the Gulf of Mexico.

On May 17, 2010, Blue Dolphin Energy Company reported financial results for the three-month period ended March 31, 2010. For the three months ended March 31, 2010, Blue Dolphin announced a net loss of $525,754 on revenues of $448,109. This is in comparison to a net loss of $1,000,009 on revenues of $536,705 for the three months ended March 31, 2009. The Company decreased their net loss primarily because of lower pipeline operating, lease operating, and general and administrative expenses.

Blue Dolphin Energy Company (BDCO) closed Monday's session at $0.24 up 20.00 percent. Volume was 95,201.

US Gold Corporation (UXG)

SmallCap Voice reported recently on US Gold Corporation (UXG), Microcap Press, Small Cap Network, and Momentum Trades did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the NYSE Amex, US Gold Corporation is a Colorado incorporated gold and silver exploration company. The Company has two significant land holdings. One of these holdings is in Nevada next to Barrick Gold's multi-million ounce Cortez project. The other holding is in Mexico, where a high-grade silver discovery has been made. US Gold Corporation has their head office in Toronto, Ontario, and a U.S. office in Reno, Nevada.

The Company received incorporation in the state of Colorado in 1979 with the name Silver State Mining. They changed their name to U.S. Gold Corporation in 1988 and to US Gold Corporation in 2007. US Gold's goal is to qualify for inclusion in the S&P 500 within 5 years.

On March 31, 2010, the Company announced an improvement in the estimated mineral resource for their 100 percent owned Gold Bar Project in Nevada. Measured and Indicated (M&I) resources increased 26 percent to 974,875 oz gold within 36.9 million tons of material with an average grade of 0.026 ounces gold per ton (opt), from 772,600 oz gold within 25.1 million tons of material with an average grade of 0.031 opt (1.053 gpt).

US Gold Corporation announced on May 18, 2010, results from twenty-five new core holes at the El Gallo Project in Sinaloa State, Mexico. The three best results since April 26, 2010 are: 12.0 ounces of silver per ton (opt) over 131.1 feet (ft) (410.2 grams of silver per tonne over 40.0 meters (m), 4.3 opt silver over 75.5 ft (149.0 gpt silver over 23.0 m) and 3.3 opt silver over 119.8 ft (114.6 gpt silver over 36.5 m).

El Gallo is a low-sulfidation, epithermal silver deposit located within the Pie de la Sierra physiographic province of the Sierra Madre Occidental Range.  The El Gallo project is near the margin of the Sinaloa Batholith. Other shallow-level porphyritic intrusives also occur within the project area. Silver mineralization is hosted in breccia and stockwork zones that occur primarily in the andesitic volcanic and intrusive rocks and to a lesser extent in quartz monzonite porphyry intrusive rocks.
Today, US Gold Corporation announced that their El Gallo Project received recognition as Sinaloa's "Discovery of the Year". The Government of Sinaloa through Mexico's Ministry of Economic Development presents this recognition to the exploration company with the most significant mineral discovery in Sinaloa State, during the previous year.

"It's been less than two years since our prospecting team took the first rock samples. Since then El Gallo has exceeded all expectations! With a number of interesting prospects now being tested around the project, it is our objective to find another El Gallo this year," stated Rob McEwen, Chairman and CEO.

Today, US Gold Corporation (UXG) closed at $3.91 up 3.99 percent. Volume was 1,269,841.

The QualityStocks Company Corner

Cellceutix Corp. (CTIX)

The QualityStocks Daily Newsletter would like to spotlight would like to spotlight Cellceutix Corp. (CTIX). Today, Cellceutix Corp. closed trading at $0.50, which was down 1.96 percent. Their volume today was 5,000 shares.

Cellceutix Corporation (CTIX) today announced it has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the KM-391 compound designed to treat autism. The company also announced today that it has completed two animal safety pharmacology studies for its cancer compound, Kevetrin™, both of which are required by the U.S. Food and Drug Administration (FDA) prior to filing an Investigational New Drug (IND) application

Cellceutix Corporation (CTIX) an emerging bio-pharmaceutical company, is in the early stages of receiving an influx of media attention and widespread notoriety within the pharmaceutical industry due to the promising results shown during the early development of a compound for the treatment of autism, KM-391, and the approaching Phase 1 clinical trials of Kevetrin™, the company's compound for the treatment of drug-resistant cancers. In addition to these two, Cellceutix currently manages a portfolio of six other promising compounds.

KM-391, a 100% novel compound, is revolutionary in that it addresses the core issues of autism, unlike the pharmaceuticals presently on the market which merely treat the symptoms that result from autism. Preliminary testing of KM-391 revealed that test animals showed a significant increase in serotonin uptake compared to controls with noticeable and measurable positive therapeutic changes. Cellceutix is rapidly developing KM-391 in response to the public outcries received by the company since the results of early testing had been made publicly available.

Kevetrin, Cellceutix's flagship product, is nearing Phase 1 clinical trials on humans with FDA regulated pre-clinical testing completed and the data being properly compiled for the IND application. While most cancer treatments today are derivatives of other compounds, Kevetrin is completely unique. Multidrug resistance, the principal mechanism by which strains of cancer develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy today and represents a huge need for novel cancer treatments.

Kevetrin has been extensively studied in animal models of lung, breast, and colon cancers, targeting carcinoma strains that have proven resistant to standard therapies available on the market today with the results showing greater tumor growth delay than present therapies and strong efficacy in mouse models with increasing dosages. A successful drug for the treatment of drug-resistant cancers is purported to generate billions of dollars in annual revenues.

The Company has procured leading figures in the health and science arenas to lead its development efforts. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as those who have been integral to mergers, acquisitions and the generation of exorbitant revenues through ground breaking therapies while holding high-level executive and research positions at industry giants such as Pfizer and Eli Lilly. Holding over a century of highly relevant experience in the pharmaceuticals industry, the team has been assembled with the specific goal of duplicating these past successes while revolutionizing much needed treatments for today's most challenging diseases. Disclaimer

Cellceutix Corp. Blog

Cellceutix Corp. News:

Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound

Cellceutix CFO Discusses Autism Drug, Kevetrin(TM) and Company Progressions With CEOCFO Interviews and News

Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers

Simulated Environment Concepts, Inc. (SMEV)

The QualityStocks Daily Newsletter would like to spotlight Simulated Environment Concepts, Inc. (SMEV). Today, Simulated Environment Concepts, Inc. closed trading at $0.04, which was up 53.85 percent. Their volume today was 328,800 shares.

Simulated Environment Concepts, Inc. (SMEV) is focused on manufacturing and distributing their patented SpaCapsule® as well as continued innovation in the areas of anti-aging, cosmetics, relaxation, cellulite reduction, and weight loss. Finding use in numerous environments such as relaxation centers, golf clubs, ski lounges, gyms, and health clubs, the SpaCapsule® provides next generation de-stressing and relaxation.

The company’s founders, Dr. Ella Frenkel and Dr. Ilya Spivak, initially capitalized Simulated Environment Concepts Inc. with several million dollars of their own money. With this initial investment, the company worked on, and succeeded in developing, the sleek and stylish looking pressurized dry water massage relaxation station.

SpaCapsule® is a full body massage, aromatherapy, audio and video entertainment system. The capsules are fused with advanced modern technology and healing methods of aromatherapy and audiovisual relaxation techniques, incorporating proprietary water-jet and pressure-jet technology that requires no on-site plumbing. Weighing approximately 500 lbs, the capsule only requires standard electric service.

Simulated Environment Concepts, Inc. (SMEV) anticipates progressive and consistent growth over the next six years. With individuals spending billions of dollars on de-stressing, weight loss, anti aging, cosmetics, massage and physical rehabilitations, the company is in a position to experience explosive growth from current levels. Disclaimer

Simulated Environment Concepts, Inc. Blog

Simulated Environment Concepts, Inc. News:

Simulated Environment Concepts Receives Additional Operation Capital

SpaCapsule Expansion Into Europe Continues to Gain Momentum

Simulated Environment Concepts Begins Penetration of Corporate Markets

Micro Identification Technologies Inc. (MMTC)

The QualityStocks Daily Newsletter would like to spotlight Micro Identification Technologies Inc. (MMTC) Today Micro Identification Technologies Inc. closed trading at $0.0470, which was up 11.90 percent. Their volume today was 274,838 shares.

Micro Identification Technologies Inc. (MMTC) is focused on becoming a global leader in developing, supporting and marketing rapid systems and processes that detect and identify microbial organisms. For several years the company has been working on the development of a breakthrough, laser-based microbial identification technology. This technology has been designed to be extremely fast and easy to use while not relying on conventional chemical or biological processing, fluorescent tags, gas chromatography or DNA analysis.

The system works by measuring scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. By measuring scattered light at specific angles, MIT’s system detects and differentiates objects the size of bacteria, protozoa, yeasts and molds.

The company’s technology offers significant advantages over today’s methods of microbial detection, including lower cost, rapid results, easier use and the ability to test for multiple bacteria in one process. The system is statistically based and includes a unique MIT Microbe Library of pre-measured light scattering identifiers - or fingerprints - derived from the measurements of tens of thousands of individual microbes for each species and subspecies to be detected.

MIT’s technology has the potential to revolutionize the $5 billion rapid microbial test market by annually saving thousands of lives and tens of millions of dollars. Since 1998, the industry has had an annual expansion of 9.2 percent - with growth projections for 30 percent annually. MIT is well positioned with its cutting-edge microbial technology as demand continues to soar as a result of major health, safety and homeland security issues. Disclaimer

Micro Identification Technologies Inc. Blog

Micro Identification Technologies Inc. News:

MIT Contracts OSI Optoelectronics to Manufacture the MIT 1000 Rapid Microbial Identification System

U.S. Equity News Features Micro Identification Technologies in the Fight Against Bacteria

Micro Identification Technologies Obtains Equity Financing

NetSol Technologies, Inc. (NTWK)

The QualityStocks Daily Newsletter would like to spotlight NetSol Technologies, Inc. (NTWK). Today, Netsol Technologies, Inc. closed trading at $0.72. Their volume today was 197,236 shares.

RedChip Visibility, a division of RedChip Companies, Inc., announced it has initiated coverage on NetSol Technologies Inc. Bill Matson, CFA, RedChip Research Analyst, stated, “Trading close to its GAAP book value and at what we believe is an unreasonably low 6.3x projected fiscal 2011 earnings, we are initiating coverage of NTWK with a Strong Buy rating and a price target of $3.00."

NetSol Technologies, Inc. (NTWK) a worldwide provider of global business services and enterprise application solutions, leverages its BestShoring(TM) practices and highly experienced resources to deliver high-quality, cost-effective solutions. The ir suite of products and services include credit and finance portfolio management systems, hospital/healthcare information management systems (HIMS), SAP consulting and services, custom development, systems integration, and technical services.

NetSol’s commitment to quality is demonstrated by its achievement of the ISO 9001, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by less than 100 companies worldwide. These distinctions are a result of adhering to rigorous quality standards, resulting in the delivery of solutions that are secure, reliable, properly planned, and meticulously executed.

Serving the global financial, healthcare, insurance, energy, and technology markets, NetSol has operations, offices, and joint ventures in Adelaide, Bangkok, Beijing, Lahore, London, Riyadh, San Francisco, and San Pedro Sula. NetSol Technologies' clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies.

NetSol Technologies, Inc. (NTWK), is well positioned with its core product offerings as it continues to expand into new international market opportunities. Looking forward, the company is very optimistic of its short-term and long-term outlook as it sees strong growth in Asia Pacific as well as the South East Asian markets, while also envisioning unlimited potential for its niche solutions and services in the Americas. Disclaimer

NetSol Technologies, Inc. Blog

NetSol Technologies, Inc. News:

RedChip Visibility Initiates Research Coverage on NetSol Technologies With Strong Buy Rating

NetSol Scores New Contracts Valued at Over $3 Million as Major Automotive Finance Company Invests in NetSol Financial Suite(TM)

Skymark Research Initiates Independent Research Coverage on NetSol Technologies, Inc.

Cellceutix Corp. (CTIX) Expedites Autism Studies in Response to Public Support; Announces Completion of Two Required Safety Pharmacology Studies

Cellceutix Corp. was pleased to announce this morning its acknowledgement of the many emails, phone calls and letters received regarding KM-391, its novel compound for the treatment of autism. In response to the outcries, Cellceutix has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the compound with the results to be released in upcoming weeks.

Cellceutix worked with the world-renowned InterEd Faculty of Clinical Research (IFCR) in India to move rapidly in the development of KM-391. The Company’s President and Chief Scientific Officer, Dr. Krishna Menon, as Chancellor of IFCR, was able to request expedited scheduling for the testing of KM-391. The prestigious Cochin University of Science & Technology (CUSAT) agreed and conducted the testing. With the research completed and data undergoing analysis, results will soon be ready for release.

“Through a great collaborative effort between our team at Cellceutix with InterEd and Cochin University, we were able to reduce scheduling time from months to weeks,” stated George Evans, Chief Executive Officer of Cellceutix. “Our years of experience in the industry have provided us with valuable resources that were very supportive in our efforts to respond to the critical need for new autism treatments.”

Cellceutix previously reported that initial testing conducted with KM-391 on a mouse model has provided promising data. In a carefully conducted study, KM-391 was given orally over a three month period to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the “no treatment” group and the “active control” (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. Because KM-391 is a novel compound and not just a derivative of an existing compound, it has taken the spotlight within the autism community and the focus of many communications to Cellceutix regarding its development.

The company also announced today that it has completed two animal safety pharmacology studies for its cancer compound, Kevetrin™, both of which are required by the U.S. Food and Drug Administration (FDA) prior to filing an Investigational New Drug (IND) application. The studies evaluated the impact of the compound on the respiratory and central nervous systems of test animals. In the respiratory study, respiratory rate, tidal volume and minute volume were measured. In the central nervous system study, neuropharmacological effects and effects on body temperature were measured. A cardiovascular safety pharmacology study is nearing completion.

“The results of these studies are very encouraging for the further development of Kevetrin,” commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The respiratory and central nervous system studies showed no biologically significant changes compared to controls. Since these studies are required by the FDA for an IND filing, their completion is a major forward step for us.”

Points International (PTSEF) Expands Partnership with Amtrak Guest Rewards

Amtrak and Points International, proprietor of Points.com, the innovative global leader in online loyalty program management, announced expansion of the Amtrak Guest Rewards® partnership today.
Members of the Amtrak Guest Rewards program will be able to share (in addition to existing Buy and Gift capabilities) points with other members via the Points.com-powered miles and points purchase platform on amtrakguestrewards.com under terms of the new agreement.

The remarkable Amtrak Guest Rewards program began in 2000, and has quickly become an industry benchmark due to its flexibility and dollar-based awarding rather than distance-based.

The genius of award-winning Points.com is that it successfully integrates diverse loyalty and rewards programs into one easy-to-use interface, where users can complete fully sanctioned transactions (Swap, Earn, Buy, Gift, Share and Redeem) using miles and points from 25 of the planet’s top rewards programs.

CEO of Points.com, Rob MacLean, expressed profound pleasure at this expanded opportunity to work with the nation’s premier rail operator, Amtrak, in offering their customers even greater value from the Amtrak Guest Rewards program.

Senior Director of Marketing at Amtrak, Michael Blakey, commented on the amazing way in which Points.com has injected additional value into the system while offering a bold new means for distribution and management, calling this precisely the sort of innovation Amtrak is always on the lookout for.

Amtrak joins a long list of other partners to take advantage of this technology including:

• Alaska Airlines Mileage Plan
• Air France KLM Flying Blue
• American Airlines AAdvantage®
• Delta Air Lines SkyMiles®
• British Airways Executive Club
• Virgin Atlantic Flying Club
• JetBlue TrueBlue
• Midwest Airlines’ Midwest Miles
• US Airways® Dividend Miles®
• Starwood Preferred Guest®
• InterContinental Hotel Group’s Priority Club® Rewards.

Talecris Biotherapeutics (TLCR) to Be Acquired by Spanish Company Grifols

Talecris Biotherapeutics is a US-based biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology, hemostasis and critical care.

The company announced today that it had signed a definite agreement to be acquired by Grifols, a global healthcare company based in Spain which is a leading producer of plasma protein therapies. Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares valued at $3.4 billion. Talecris shareholders will receive $19 in cash and 0.641 in Grifols shares for each share of Talecris. The Grifols will be listed on the NASDAQ.

The combination of Grifols and Talecris will create a vertically integrated and diversified international plasma protein therapies company. The new company brings together complementary geographic footprints and products, as well as increased manufacturing scale. For more information on the details of the combined company, please visit either www.talecris.com or www.grifols.com.

Grifols chairman and CEO Victor Grifols commented on the deal, “The acquisition of Talecris furthers our vision to better serve patients and health care professionals with innovative products, a strong clinical research capability and new research into recombinant therapies. We look forward to combining the strengths of both companies to improve the quality of the lives of patients around the world, while positioning the enlarged group for long term profitable growth.”

GigOptix, Inc. (GGOX) Appoints Frank Schneider to Board of Directors

GigOptix Inc., a leading supplier of electronic and electro-optic semiconductor products for fiber-optic communications systems, today announced the appointment of Frank W. Schneider to the GigOptix Board of Directors, replacing Dr. Joseph J. Vallner, who is retiring from the board. Mr. Schneider will serve as an independent director and member of the Audit and Compensation Committees.

Mr. Schneider brings with him over 40 years of electronics and semiconductor industry experience, serving on the boards and executive management teams of both privately held and publicly traded companies. He recently retired from MKS Instruments, Inc., where he was Vice President and General Manager, and continues to provide consulting services. He is currently on the Board of Directors for Micrel, Inc.

Previously, Mr. Schneider served as President and CEO at ION Systems, a privately held maker of electrostatic management systems. He also served at GHz Technology, a privately held manufacturer of RF power transistors that was merged into Advanced Power Technology, Inc., where he was COO of the RF Products Group. Mr. Schneider was also a member of the technical advisory board of Neomagic, and was on the board of GMT Microelectronics. He began his career at Corning Electronics, moving to Philips Semiconductor, then known as Signetics Corporation. He was also a group vice president at Sharp Electronics.
Mr. Schneider received his B.S. in Electrical Engineering from West Virginia University, and an MBA from Northwestern University Kellogg School of Management. He also completed executive post graduate programs at Stanford University and the Wharton School of Business.

GigOptix Chairman, President, and CEO, Dr. Avi Katz, said of the appointment, “I am very pleased to welcome Frank Schneider to our Board of Directors. In addition to strengthening our Board with his extensive industry knowledge and executive management experience, Mr. Schneider brings a unique international perspective to GigOptix, having resided in Japan for five years. With Mr. Schneider’s appointment, we now have a board comprised of four independent directors whose diverse experience and exceptional strategic counsel will be key factors in the achievement of our goals and vision going forward.”
 


Sponsors of the Day

 

The QualityStocks Public Company Sponsor News

Micro Identification Technologies Inc. (MIT) (MMTC) MIT Contracts OSI Optoelectronics to Manufacture the MIT 1000 Rapid Microbial Identification System

QualityStocks


 

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336